Results 121 to 130 of about 9,107,460 (340)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system

Frontiers in Public Health
BackgroundAn increasing number of countries worldwide, including China, have adopted Health Technology Assessment (HTA) and pharmacoeconomic (PE) principles, either comprehensively or partially, to inform drug reimbursement decisions.
Xiaochen Peng, Xiaochen Peng, Haiyin Wang, Hui Sun, Xiaoxiao Qin, Zhe Huang   +5 more
doaj   +1 more source

The impact of diagnosis subject to reimbursement on life expectancy, the ability to work, and the quality of life: The experts’ assessment

SHS Web of Conferences, 2014
The ex-post retrospective analysis of the health care reform in Latvia has been performed by several authors; therefore in writing this paper, the author also considered it essential to try and predict its future prospects, specifically, to carry out an ...
Araja D.
doaj   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Mapping heterogeneity in the management of malignant pleural effusions with indwelling pleural catheters in Denmark - a national survey

European Clinical Respiratory Journal
Background Malignant pleural effusion (MPE) affects up to 20% of cancer patients, causing dyspnea and frequent hospitalizations. Treatment includes thoracentesis, pleurodesis, and indwelling pleural catheters (IPC).
Aras K. M. Ali, Katrine Fjaellegaard, Christian B. Laursen, Søren Helbo Skaarup, Karin Armbruster, Uffe Bødtger   +5 more
doaj   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Colocating Health Services: A Way to Improve Coordination of Children's Health Care? [PDF]

, 2008
Based on a literature review and interviews, outlines the benefits, costs, and issues of pediatric practices' co-location with other providers and services.
Susanna Ginsburg
core  

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source